European Alzheimer's Disease Medication Market

Launch of Disease-modifying Drugs expected to Boost Market Growth
Share this:
Published: 27 Sep 2012

The key objective of this research service  is to study the European Alzheimer’s disease medication market based on the three major classes of drugs namely acetylcholinesterase inhibitors, NMDA receptor antagonists and new mechanism/ disease modifying drugs and identify the key current and future trends shaping these market segments.  It also aims to provide valuable insights on the potential drug candidates in the pipeline  and analyse the competitive landscape  with respect to the key existing market participants and promising companies in the future. Revenue forecasts of total market as well as key five European countries is also provided.



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..